Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA Ties Up with TesoRx on Oral Testosterone Therapy
January 5, 2017
- Takeda Makes Foray into Consumer Diagnostic Biz with Ovulation, Pregnancy Tests
December 28, 2016
- Opdivo Filed for Gastric Cancer in Japan: Ono
December 28, 2016
- AZ Returns Meropenem Rights in Southeast Asia, HK to Sumitomo Dainippon
December 27, 2016
- SBI, Kubota to Form JV for Ophthalmic Drugs, Devices
December 27, 2016
- Aspen Japan to Launch Imigran AG on Jan. 16
December 27, 2016
- 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
- Towa to Discontinue Marketing Cabergoline Generic due to Failure in Dissolution Testing
December 27, 2016
- Eisai, Keio Univ. Seal 10-Year Collaboration on Dementia Research
December 26, 2016
- Ono In-Licenses OmniAb Antibody Producing Platforms from US Biotech
December 26, 2016
- Chugai Licenses Marine-Derived Cancer Med from Spain’s PharmaMar
December 26, 2016
- Hemophilia Med Emicizumab Hits PIII Target; Global Filings Slated for 2017
December 26, 2016
- Keytruda Filed for Hodgkin’s Lymphoma, 3rd Indication in Japan
December 26, 2016
- Sawai Prevails in Patent Suit over Elplat
December 26, 2016
- New Indication Added to Plavix Generics to Fill Gap with Originator
December 22, 2016
- Janssen’s MM Med Daratumumab Filed in Japan
December 22, 2016
- Sumitomo Dainippon to Buy US Hematology Startup Tolero
December 22, 2016
- Otsuka, Akebia Form US Collaboration on Anemia Med Vadadustat
December 22, 2016
- Astellas Completes Acquisition of Ganymed
December 22, 2016
- Ono Slashes Opdivo Sales Outlook on 50% Price Cut
December 22, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…